Deals in Depth: February 2011
Executive SummaryAstellas added Phase III tivozanib to its pipeline in a $700mm deal with Aveo. Diagnostics and analytical testing companies fared well in M&A, including Danaher's $6.8 billion acquisition of Beckman Coulter. Biopharma financing jumped 7% to $1.9 billion, and device companies also raised more money than last month - $367 million vs. $189 million.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.